Broncus Holding Corporation (HKG:2216)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
1.270
-0.010 (-0.78%)
Apr 21, 2026, 9:44 AM HKT
Market Cap674.66M +56.5%
Revenue (ttm)1.35M -97.9%
Net Income-139.13M
EPS-0.29
Shares Out527.08M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume29,000
Average Volume1,311,622
Open1.340
Previous Close1.280
Day's Range1.230 - 1.350
52-Week Range1.000 - 3.720
Beta1.25
RSI43.72
Earnings DateMar 31, 2026

About Broncus Holding

Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, and internationally. The company offers InterVapor, a thermal vapor treatment system to treat chronic obstructive pulmonary disease (COPD); BroncAblate Radiofrequency Ablation System, a transbronchial interventional treatment product for lung cancer; Targeted Lung Denervation (TLD) Radiofrequency Ablation System for the treatment of COPD; H-Marker, a pulmonary surgical marker can be used... [Read more]

Sector Healthcare
Founded 2012
Employees 171
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2216
Full Company Profile

Financial Performance

In 2025, Broncus Holding's revenue was $174,000, a decrease of -97.86% compared to the previous year's $8.13 million. Losses were -$17.88 million, 16.8% more than in 2024.

Financial numbers in USD Financial Statements